D-0828-2020 Class II Terminated

Recalled by Ascend Laboratories LLC — Parsippany, NJ

FDA drug recall D-0828-2020 was initiated by Ascend Laboratories LLC on Jan 24, 2020 and is designated Class II. Reason for recall: cGMP Deviations; Olmesartan Medoximil Tablets 20 mg was released in error with alternate API source prior to filing and approval of Prior Approval Supplement. The recall status is terminated (terminated Oct 29, 2021). Affected quantity: 192 Bottles.

Recall details

Product Type
Drugs
Report Date
Feb 12, 2020
Initiation Date
Jan 24, 2020
Termination Date
Oct 29, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
192 Bottles

Product description

Olmesartan Medoxomil Tablets 20 mg, Rx Only, 90 Tablets per Bottle, Manufactured by: Alkem Laboratories Ltd., Mumbai - 400 013 INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC 67877-446-90.

Reason for recall

cGMP Deviations; Olmesartan Medoximil Tablets 20 mg was released in error with alternate API source prior to filing and approval of Prior Approval Supplement.

Distribution pattern

Nationwide in the U.S.

Code information

Lot #: 19122552, Exp 7/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0828-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0828-2020. Report a data issue: hello@regdatalab.com.